LBG consultants interviewed CAR-T Innovators and Manufacturers to better understand the difficulties surrounding manufacturing. Specifically, the Innovators were asked about the criteria they look for in a CDMO. Without exception, Innovator companies stated CDMO capacity and flexibility were top priorities. These criteria are priorities for Innovators because the drug product needs to be manufactured when the patient material is available. Ensuring Innovators can fulfill clinical development milestones is also a consideration with respect to CDMO capacity and flexibility. In determining who to use for a CDMO, there was no perfect solution, however early CDMO selection and scheduling are critical to maintain Innovators’ clinical development timeline.